Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

New Film-Coated Tablet Formulation of Deferasirox Is Well Tolerated in Patients with Thalassemia or MDS: Results of the Randomized, Phase II E.C.L.I.P.S.E. Study

Ali T. Taher, MD PhD, Raffaella Origa, Silverio Perrotta, Alexandra Kouraklis, Giovan Battista Ruffo, Antonis Kattamis, MD, Ai-Sim Goh, Annelore Cortoos, Vicky Huang, Marine Weill, Raquel Merino Herranz, John B. Porter, BA MB BChir MRCP(Path) FRCP(Path) MD

Blood (2016) 128 (22): 1285.

https://doi.org/10.1182/blood.V128.22.1285.1285

Published: 2016

Journal Articles

Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinenthal Collaborative Study

Ali Amid, MD, Rebecca Leroux, BScN, Manuela Merelles-Pulcini, MSc, Saeed Yassobi, MD, Antoine N Saliba, MD, Richard Ward, MSc, MRCP, FRCPath, Mehran Karimi, MD, Ali T. Taher, MD PhD, Robert J Klaassen, MD, Melanie Kirby-Allen, MD

Blood (2016) 128 (22): 3633.

https://doi.org/10.1182/blood.V128.22.3633.3633

Published: 2016

Journal Articles

Improved Patient-Reported Outcomes with a Film-Coated Versus Dispersible Tablet Formulation of Deferasirox: Results from the Randomized, Phase II E.C.L.I.P.S.E. Study

Blood (2016) 128 (22): 850.

https://doi.org/10.1182/blood.V128.22.850.850

Published: 2016

Journal Articles

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Yesim Aydinok, MD, Zeynep Karakas, MD, Elena Cassinerio, MD, Noppadol Siritanaratkul, MD, Antonis Kattamis, MD, Aurelio Maggio, MD, Norbert Hollaender, PhD, Bruyère Mahuzier, Pharm D, Brian Gadbaw, MD, Ali T. Taher, MD PhD

Blood (2016) 128 (22): 852.

https://doi.org/10.1182/blood.V128.22.852.852

Published: 2016

Journal Articles

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

John B Porter, MD, Mohsen Elalfy, MD, Ali T Taher, MD, Lee Lee Chan, MD, Szu-Hee Lee, MD, Pranee Sutcharitchan, MD, Yesim Aydinok, MD, Subhashish Chakravarty, PhD, Ali El-Ali, MD, Amal El-Beshlawy, MD/Professor

Blood (2014) 124 (21): 52.

https://doi.org/10.1182/blood.V124.21.52.52

Published: 2014

Journal Articles

Multivariate Analysis Evaluating Potential Predictors of Cardiac T2* Where Cardiac Magnetic Resonance Imaging (CMR) Availability Is Limited

John B Porter, MD, Ali T Taher, MD PhD, Yesim Aydinok, MD, Amal El-Beshlawy, MD/Professor, Mohsen El-Alfy, MD, Ali El-Ali, MD, Subhashish Chakravarty, PhD, M Domenica Cappellini, MD

Blood (2014) 124 (21): 1366.

https://doi.org/10.1182/blood.V124.21.1366.1366

Published: 2014

Journal Articles

Relative Trends in Myocardial T2* Versus Myocardial Iron Concentration As Representations of Myocardial Iron Chelation Efficacy in Patients with β Thalassemia Major Treated with Deferasirox for up to 3 Years

John B Porter, MD, Ali T Taher, MD, Yesim Aydinok, MD, Amal El-Beshlawy, MD/Professor, Mohsen Elalfy, MD, Ali El-Ali, MD, Nathalie Barbier, M Domenica Cappellini, MD

Blood (2014) 124 (21): 4040.

https://doi.org/10.1182/blood.V124.21.4040.4040

Published: 2014

Journal Articles

Outcome Of Bone Marrow Transplantation In Lebanese Children With β-Thalassemia Major

Adlette Inati, MD, Javid Gaziev, MD, Hussein A Abbas, PhD, Serge Korjian, BSc, Yazan Daaboul, BSc, Mario Kahale, MD, Katia Paciaroni, MD, Gioia de Angelis, MD, Ali T Taher, MD, Therese Abi Nasr, MD, Suzan Koussa, MD, Guido Lucarelli, MD

Blood (2013) 122 (21): 5505.

https://doi.org/10.1182/blood.V122.21.5505.5505

Published: 2013

Journal Articles

A Phase 2 Trial Of The Fetal Hemoglobin Inducer HQK-1001 (2,2-dimethylbutyrate, Sodium Salt) In Non-Transfusion-Dependent β-Thalassemia

Adlette Inati, MD, Mario Kahale, MD, Susan P Perrine, MD, Ali T Taher, MD, Suzanne Koussa, MD, Hussein A Abbas, PhD, Therese Abi Nasr, MD, Richard G. Ghalie, MD

Blood (2013) 122 (21): 2261.

https://doi.org/10.1182/blood.V122.21.2261.2261

Published: 2013

Journal Articles

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

John Porter, MD, Ali T Taher, MD, Yesim Aydinok, MD, Maria D Cappellini, Antonis Kattamis, MD, Ali El-Ali, MD, Nicolas Martin, MS, Dudley Pennell, MD, FRCP

Blood (2013) 122 (21): 1016.

https://doi.org/10.1182/blood.V122.21.1016.1016

Published: 2013

Journal Articles

Serum Ferritin Levels and Morbidity in β-Thalassemia Intermedia: A 10-Year Cohort Study

Khaled M Musallam, MD, PhD, Maria D Cappellini, Shahina Daar, Mehran Karimi, Amal El-Beshlawy, Ali T Taher, MD

Blood (2012) 120 (21): 1021.

https://doi.org/10.1182/blood.V120.21.1021.1021

Published: 2012

Journal Articles

Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network

Claudia R. Morris, MD, Hae-Young Kim, DrPH, John C Wood, MD, Felicia Trachtenberg, PhD, Elizabeth S Klings, MD, John B. Porter, MD, Nancy Sweeters, RN, PNP, Nancy F Olivieri, MD, Janet L. Kwiatkowski, MD, Sylvia Titi Singer, MD, Ali T Taher, MD, Ellis J. Neufeld, MD, PhD, Alexis A. Thompson, MD, MPH, Vandana Sachdev, M.D., Sandra K Larkin, MS, Jung H Suh, PhD, Frans A Kuypers, PhD, Elliott Vichinsky, MD

Blood (2012) 120 (21): 1023.

https://doi.org/10.1182/blood.V120.21.1023.1023

Published: 2012

Journal Articles

Evaluation of the 5 Mg/g Liver Iron Concentration Threshold and Its Association with Vascular and Endocrine/Bone Morbidity in β-Thalassemia Intermedia

Khaled M Musallam, Maria D Cappellini, Ali T Taher, MD

Blood (2012) 120 (21): 1024.

https://doi.org/10.1182/blood.V120.21.1024.1024

Published: 2012

Journal Articles

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Ali T Taher, MD, John B Porter, MD, Vip Viprakasit, MD, DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppadol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Dany Habr, MD, Jacqueline Ros, PhD, Zewen Zhu, M Domenica Cappellini, MD

Blood (2012) 120 (21): 3258.

https://doi.org/10.1182/blood.V120.21.3258.3258

Published: 2012

Journal Articles

Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network.

Claudia R. Morris, MD, Hae-Young Kim, DrPH, John C Wood, MD, Ph.D, Felicia Trachtenberg, PhD, Elizabeth S Klings, MD, John B. Porter, MD, Nancy Sweeters, RN, PNP, Nancy F Olivieri, MD, Janet L. Kwiatkowski, MD, Sylvia Titi Singer, MD, Ali T Taher, MD, Ellis J. Neufeld, MD, PhD, Alexis A. Thompson, MD, MPH, Sandra K Larkin, MS, Jung H Suh, PhD, Elliott Vichinsky, MD, Frans A Kuypers, PhD

Blood (2012) 120 (21): 2122.

https://doi.org/10.1182/blood.V120.21.2122.2122

Published: 2012

Journal Articles

A Randomized, Open-Label, Multicenter, Dose Escalation Study of HQK-1001 (2,2-Dimethylbutyrate, Sodium Salt) in Sickle Cell Disease

Abdullah Kutlar, MD, Marvin Reid, PhD, Ali T Taher, MD, Adlette Inati, MD, Miguel R. Abboud, MD, Amal El-Beshlawy, MD, George R. Buchanan, MD, Hedy Smith, MD PhD, Kenneth I. Ataga, MD, Nebu Koshy, MD, FACP, Lynne D Neumayr, MD, Punam Malik, M.D., Ofelia A. Alvarez, MD, Richard Ward, MBBS, MRCP, FRCPath, J Michael White, PhD, Elsa Johnson, MBA, Richard G. Ghalie, MD

Blood (2012) 120 (21): 998.

https://doi.org/10.1182/blood.V120.21.998.998

Published: 2012

Journal Articles

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

Ali T Taher, MD, John B. Porter, MD, Vip Viprakasit, MD; DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppodol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Jacqueline Ros, PhD, Yiyun Zhang, Dany Habr, MD, M. Domenica Cappellini, MD

Blood (2011) 118 (21): 902.

https://doi.org/10.1182/blood.V118.21.902.902

Published: 2011

Journal Articles

A Phase 2 Clinical Study of HQK-1001 (2,2-dimethylbutyrate, sodium salt), a Fetal Hemoglobin Inducer, in Patients with Sickle Cell Disease

Abdullah Kutlar, MD, Adlette Inati, MD, Ali T Taher, MD, Amal El-Beshlawy, MD, Marvin Reid, PhD, Miguel R. Abboud, MD, Hedy Smith, MD, PhD, Kenneth I. Ataga, MD, George R. Buchanan, MD, Punam Malik, MD, Nebu Koshy, MD, Lynne Neumayr, MD, Maria Aiello, MA, Elsa Johnson, MBA, J Michael White, PhD, Richard G. Ghalie, MD

Blood (2011) 118 (21): 1066.

https://doi.org/10.1182/blood.V118.21.1066.1066

Published: 2011

Journal Articles

Relationship Between Total Iron Removed by Phlebotomy and Iron Removed From the Liver in Pediatric Thalassemia Major Patients Following Curative Stem Cell Transplant

Adlette Inati, MD, Nada Sbeiti, MD, Ali T Taher, MD, Suzanne Koussa, MD, Timothy G St Pierre, PhD

Blood (2011) 118 (21): 5300.

https://doi.org/10.1182/blood.V118.21.5300.5300

Published: 2011

Journal Articles

1-Year Results From A Prospective Randomized Trial Comparing Phlebotomy with Deferasirox for the Treatment of Iron Overload in Pediatric Patients with Thalassemia Major Following Curative Stem Cell Transplantation

Adlette Inati, MD, Nada Sbeiti, MD, Evelyne Khoriaty, MD, M Domenica Cappellini, MD, Suzanne Koussa, MD, Therese Abi Nasr, MD, Khaled M Musallam, MD, Ali T Taher, MD

Blood (2011) 118 (21): 904.

https://doi.org/10.1182/blood.V118.21.904.904

Published: 2011

NARROW

New Film-Coated Tablet Formulation of Deferasirox Is Well Tolerated in Patients with Thalassemia or MDS: Results of the Randomized, Phase II E.C.L.I.P.S.E. Study

Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinenthal Collaborative Study

Improved Patient-Reported Outcomes with a Film-Coated Versus Dispersible Tablet Formulation of Deferasirox: Results from the Randomized, Phase II E.C.L.I.P.S.E. Study

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

Multivariate Analysis Evaluating Potential Predictors of Cardiac T2* Where Cardiac Magnetic Resonance Imaging (CMR) Availability Is Limited

Relative Trends in Myocardial T2* Versus Myocardial Iron Concentration As Representations of Myocardial Iron Chelation Efficacy in Patients with β Thalassemia Major Treated with Deferasirox for up to 3 Years

Outcome Of Bone Marrow Transplantation In Lebanese Children With β-Thalassemia Major

A Phase 2 Trial Of The Fetal Hemoglobin Inducer HQK-1001 (2,2-dimethylbutyrate, Sodium Salt) In Non-Transfusion-Dependent β-Thalassemia

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

Serum Ferritin Levels and Morbidity in β-Thalassemia Intermedia: A 10-Year Cohort Study

Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network

Evaluation of the 5 Mg/g Liver Iron Concentration Threshold and Its Association with Vascular and Endocrine/Bone Morbidity in β-Thalassemia Intermedia

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network.

A Randomized, Open-Label, Multicenter, Dose Escalation Study of HQK-1001 (2,2-Dimethylbutyrate, Sodium Salt) in Sickle Cell Disease

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

A Phase 2 Clinical Study of HQK-1001 (2,2-dimethylbutyrate, sodium salt), a Fetal Hemoglobin Inducer, in Patients with Sickle Cell Disease

Relationship Between Total Iron Removed by Phlebotomy and Iron Removed From the Liver in Pediatric Thalassemia Major Patients Following Curative Stem Cell Transplant

1-Year Results From A Prospective Randomized Trial Comparing Phlebotomy with Deferasirox for the Treatment of Iron Overload in Pediatric Patients with Thalassemia Major Following Curative Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only